Drug Pricing
The Latest
Behind The Government's Lawsuit Over Gilead's Alleged PrEP Patent Infringement.
A report on the research and activist work that led to the federal government taking nearly unprecedented action against the pharmaceutical company.
Facing Atlanta's HIV Bureaucracy Gave Me a Lesson in Hardship
After finally being connected to care, health activist Mason runs into more obstacles -- and another unexpected wait for lifesaving medication.
In Post-Katrina New Orleans, HIV Rates Have Fallen While PrEP and HIV Care Have Increased
Poverty, stigma and racial health disparities drive HIV rates that are among the nation's highest. But expanded Medicaid and PrEP access seem to have contributed to a recent drop in new cases.
Is Marianne Williamson's Record on AIDS as Great as She Claims?
As the 2020 presidential hopeful touts her HIV activist record, doubts remain as to whether her version of events is the full truth.
HIV and the Charlotte Metro Area: What You Need to Know
In North Carolina, Greater Charlotte is booming, but income disparity, Immigration and Customs Enforcement (ICE) raids on immigrants, and spread-out service providers all create challenges to reversing HIV rates.
Why Are HIV Meds So Expensive, and What Can We Do About It?
Why do Americans and their insurers pay more for some drugs and less for others? And who decides what a fair price for a drug should be, and how can manufacturers and health plans be compelled to improve access and affordability?
HIV Treatment Activists Discuss Their Treatment History, and Their Rights as Big Pharma Consumers
First, they were diagnosed. Then, they started treatment. Then, they advocated for others. In this roundtable, three treatment activists discuss their journeys.
Starting HIV Treatment and Corporate Greed: An Activist's Perspective
From protesting "big pharma" about the cost of meds, to being on meds himself, Marco Benjamin's journey with starting treatment is nuanced, and the subject of this op-ed.
The Real Cost of Development
The pharmaceutical industry just doesn't get it. Here we are on the cusp of a revolution in medicine, with genomic insights likely to yield a generation of medicinal products safer and more effective than any before; with burgeoning markets, record p...